Search

The purpose of this study was to assess the ability of the new blood pool contrast agent meglumine-carboxymethyldextran-ethylenediamino-gadoterate (CMD-A2-Gd-DOTA) to depict acute occlusive myocardial infarction (AMI). First-pass gradient-echo and delayed spin-echo magnetic resonance imaging (MRI) was performed 5 days after induction of AMI in a pig model. MRI was correlated with pathology. First-pass imaging with CMD-A2-Gd-DOTA allowed detection of infarcted myocardium in all pigs (n = 7). The infarction was recognized as a black spot on MRI as well as on a parametric image. The signal intensity (SI) amplitudes of normal versus infarcted myocardium were 80.55 +/- 18.61 versus 8.48 +/- 15.50 on MRI and 81.62 +/- 18.50 versus 1.61 +/- 3.73 on the parametric image (both P values < 0.001. The contrast ratio between normal and infarcted myocardium was not significantly improved on spin-echo MRI, suggesting largely intact vascular integrity outside the occluded area. CMD-A2-Gd-DOTA is useful for depicting occlusive myocardial infarction by first-pass MRI. Spin-echo imaging is promising in assessing vascular integrity. J. Magn. Reson. Imaging 1999;10:170-177., (Copyright 1999 Wiley-Liss, Inc.)

Purpose: To assess the value of P760, a gadolinium chelate with slow interstitial diffusion and high relaxivity, for magnetic resonance (MR) imaging of acute myocardial infarction in pigs., Materials and Methods: First-pass gradient-echo MR imaging and spin-echo MR imaging were performed with P760 and then with gadoterate meglumine in eight pigs with occlusive acute myocardial infarction. P760 signal intensity enhancement and clearance were compared with those of gadoterate meglumine., Results: The first-pass enhancement ratio of P760 in normal myocardium was higher than that in infarcted myocardium (1.37 +/- 0.06 [SEM] vs 1.05 +/- 0.03, P = .03). The myocardial first pass showed a blood pool-like curve for P760. The blood pool enhancement ratio 40 seconds after injection was higher for P760 than for gadoterate meglumine (left ventricular cavity, 1.75 +/- 0.06 vs 1.45 +/- 0.06, P = .009). Spin-echo MR imaging showed improved contrast between normal and infarcted myocardium after P760 administration: The ratio before contrast material administration was 0.21 +/- 0.03, that at 15 minutes was 0.48 +/- 0.05 (P = .002), and that at 25 minutes was 0.47 +/- 0.07 (P = .003)., Conclusion: P760 is an MR imaging contrast agent characterized by low diffusion, a blood pool effect soon after low-dose administration, and fast elimination. This agent is useful for improved myocardial perfusion MR imaging of acute myocardial infarction.

Meglumine-carboxymethyldextran-ethylenediamino-gadoterate (CMD-A2-Gd-DOTA) was evaluated as a blood pool contrast agent for magnetic resonance angiography (MRA). MRA of large body vasculature was performed in seven pigs using a gradient-echo sequence at 1.5 T before and after 0.05 mmol/kg CMD-A2-Gd-DOTA injection. The signal- and contrast-to-noise ratios (SNRs, CNRs) were measured, as well as the pharmacokinetic clearance pattern. CMD-A2-Gd-DOTA visualized the vasculature with a high SNR and CNR for over 110 minutes after injection, but for the renal arteries the CNR was only significant within 15 minutes. Image quality was maximum within 15 minutes, producing enhancement (mean +/- SD) as follows: aortic arch 738 +/- 272%, abdominal aorta 393 +/- 123%, left renal artery 202 +/- 95%, right renal artery 248 +/- 107%, inferior vena cava 371 +/- 129%, and portal vein 513 +/- 145%, all P values < or =0.001. The clearance pattern was triphasic. Due to the excellent enhancement of vasculature without background enhancement, CMD-A2-Gd-DOTA is potentially a useful MR blood pool contrast agent for equilibrium phase MRA.

The objective of this study was to assess the potential of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) to identify myocardial ischemia and reperfusion in the isolated rat heart model. Ischemia was induced by reducing the perfusion pressure from 80 to 30 mm Hg for 2 hours. Hearts were not reperfused, or were reperfused for 20 minutes or for 2 hours. Perfusion was performed with Evans blue dye and/or Gd-DTPA for 3 minutes. Twenty isolated rat hearts were perfused according to the Langendorff method, and divided into five groups according to the perfusion status and the use of Gd-DTPA and/or Evans blue as perfusion markers. The Evans blue distribution in the hearts was assessed by point-counting volumetry. The Gd-DTPA distribution was assessed by magnetic resonance microimaging at 6.3 T field strength. Evans blue staining clearly identified areas with "no flow" or "no reflow." Perfusion with Gd-DTPA enhanced signal intensity significantly, both in ischemic and reperfused myocardium. Signal intensity in hearts reperfused for 2 hours was increased significantly compared to nonreperfused ischemic hearts, but not to ischemic hearts reperfused for 20 minutes. Magnetic resonance imaging with the aid of Gd-DTPA can identify ischemia and reperfusion in the isolated rat heart, dependent on residual perfusion.

To evaluate first pass in the right ventricular (RV) and left ventricular (LV) cavities and myocardial perfusion, subsecond MR imaging was performed in seven normal subjects following intravenous bolus injection of Gd-DTPA. After the baseline scans, sequential ECG-triggered images were obtained every three to four RR intervals. The procedure consisted of an initial presaturation pulse (150 degrees), and the acquisition time for one image was approximately 500 ms with 64 phase-encoding steps. After bolus administration of Gd-DTPA (0.05 mmol/kg body wt), progressively increasing signal intensities were observed in the RV cavity, the LV cavity, and the myocardial wall. Gadolinium DTPA enhanced subsecond MR offers temporal information of the first transit in the cardiac chambers and may provide useful clinical reference data for assessment of myocardial perfusion in patients with coronary artery disease.

The value of gadolinium enhancement to enable detection of infarcted myocardium at T1-weighted magnetic resonance (MR) imaging was assessed in 84 patients after acute myocardial infarction (AMI). Five healthy subjects served as controls. All patients underwent MR imaging before and 20 minutes after administration of gadopentetate dimeglumine. Contrast enhancement of normal myocardium varied 7% +/- 4 after administration of gadopentetate dimeglumine. Mean intensity ratio after gadolinium enhancement in group 1 (imaging less than 1 week after AMI), group 2 (imaging 1-3 weeks after AMI), and group 3 (imaging 3-6 weeks after AMI) was significantly higher than before gadolinium enhancement. In group 4 (imaging more than 6 weeks after AMI), no significant difference was observed. After gadolinium enhancement, the intensity ratio was abnormally increased in 82% of the MR examinations in group 1, in 62% of group 2, in 58% of group 3, and in 12% of group 4. Gadolinium enhancement improved visualization of myocardial infarction at MR imaging up to 6 weeks after onset of symptoms and had a maximal effect within 1 week after AMI.

Magnetic resonance images were obtained from 32 patients with acute myocardial infarction, using a four-echo technique (echo time (TE) = 30, 60, 90, and 120 ms) pregadolinium(Gd)-DTPA injection and a TE = 30 ms sequence pre- and post-Gd-DTPA. Intensity ratios of infarcted and normal myocardium were calculated, as were contrast-to-noise and signal-to-noise ratios. The four intensity ratios pre-Gd-DTPA were 1.20 +/- 0.15, 1.42 +/- 0.22, 1.78 +/- 0.38, and 1.99 +/- 0.60 for TE = 30, 60, 90, and 120 ms, respectively, and 1.42 +/- 0.19 post-Gd-DTPA (p = NS for post-Gd-DTPA vs TE = 60, p = 0.007 for TE = 90 vs TE = 120, p less than 0.0001 for all other comparisons). The four contrast-to-noise ratios pre-Gd-DTPA were 1.69 +/- 0.97, 2.69 +/- 1.13, 3.17 +/- 1.15, and 2.90 +/- 1.09 for TE = 30, 60, 90, and 120 ms, respectively, and 2.71 +/- 1.26 post-Gd-DTPA (p = NS for post-Gd-DTPA vs TE = 60, 90, and 120, p = NS for TE = 120 vs TE = 60 and 90, p less than 0.01 for all other comparisons). The four signal-to-noise ratios pre-Gd-DTPA were 8.67 +/- 1.47, 6.52 +/- 0.76, 5.20 +/- 0.64, 4.17 +/- 0.53 for TE = 30, 60, 90, and 120 ms, respectively, and 9.17 +/- 1.92 post-Gd-DTPA (p = 0.03 for post-Gd-DTPA vs TE = 30, p less than 0.0001 for all other comparisons). In conclusion, the detectabilities of acute myocardial infarction were similar at TE = 60 ms and at Gd-DTPA enhanced short-TE MR imaging. However, image quality proved to be superior using the Gd-DTPA enhanced short-TE technique.

In 21 patients with proved acute myocardial infarction, the size of the infarct was estimated with serial magnetic resonance (MR) imaging after intravenous injection of gadolinium diethylenetriaminepentaacetic acid (DTPA) (0.2 mmol per kilogram of body weight). Early reperfusion after thrombolytic therapy or percutaneous transluminal coronary angioplasty performed during the acute phase of infarction was documented with coronary angiography in nine patients (group 1). In 12 patients (group 2), no reperfusion was achieved (n = 5) or no thrombolytic therapy was given (n = 7). All group 2 patients were considered to have no reperfusion. Infarct sizes measured with MR imaging were significantly smaller in group 1 than in group 2 at 8 days +/- 4 after infarct onset (8% +/- 5% vs 15% +/- 4%, respectively; P less than .001). Serial MR images showed individual variations in infarct size, findings that may be clinically significant. Estimation of infarct size with Gd-DTPA-enhanced MR imaging is accurate in demonstrating the effect of successful reperfusion therapy on infarct size.

Indium-111 antimyosin F(ab')2 was used in a series of scintigraphic studies on experimentally induced myocardial infarctions in pigs. Antimyosin distribution recorded by planar images of in vivo pigs and by single photon emission computed tomography (SPECT) of excised hearts delineated areas of myocardial necrosis if infarct volume exceeded 3.3 cm3. Scintigraphic images were compared with magnetic resonance images (MRI) obtained from excised hearts and with photographs of slices of the hearts. Infarct size and localization determined with antimyosin were compared. The MR images, with or without gadolinium-DTPA (Gd-DTPA), of the in vivo pigs were all false-negative; some myocardial wall thinning and high bloodpool signals were visible. Results show that both the antimyosin and the MR technique are specific methods for the visualization of induced myocardial necrosis in this animal model. However, the use of antimyosin is limited to a period ranging from 24 to 72 hours after infarction.

To evaluate the usefulness of the paramagnetic contrast agent Gadolinium-DTPA (diethylenetriaminepentaacetic acid) in Magnetic Resonance Imaging of acute myocardial infarction, we studied a total of 45 patients with a first acute myocardial infarction by ECG-gated magnetic resonance imaging before and after intravenous administration of 0.1 mmol/kg Gadolinium-DTPA. All patients received thrombolytic treatment by intravenous streptokinase. The magnetic resonance imaging studies were performed after a mean of 88 h (range 15-241) after the acute onset of acute myocardial infarction. Five patients without evidence of cardiac disease served as controls. Spin-echo measurements (TE 30 ms) were made using a Philips Gyroscan (0.5 Tesla) or a Teslacon II (0.6 Tesla). The 45 patients were divided into four groups of patients. In Group I (5 patients) Gadolinium-DTPA improved the detection of myocardial infarction by Gadolinium-DTPA. In Group II (20 patients) the magnetic resonance imaging procedure was repeated every 10 min for up to 40 min following administration of Gadolinium-DTPA. Optimal contrast enhancement was obtained 20-25 min after Gadolinium-DTPA. In Group III (27 patients) signal intensities were significantly higher in the patients who underwent the magnetic resonance imaging study more than 72 h (mean 120) after the acute event, suggesting increased accumulation of Gadolinium-DTPA in a more advanced stage of the infarction process. In Group IV (45 patients) Gadolinium-DTPA was administered in an attempt to distinguish between reperfused and nonreperfused myocardial areas after thrombolytic treatment for acute myocardial infarction.(ABSTRACT TRUNCATED AT 250 WORDS)

The diagnostic value of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in patients treated by thrombolysis for acute myocardial infarction was assessed in 27 consecutive patients who had a first acute myocardial infarction (14 anterior, 13 inferior) and who underwent thrombolytic treatment and coronary arteriography within 4 hours of the onset of symptoms. Magnetic resonance imaging was performed 93 hours (range 15-241) after the onset of symptoms. A Philips Gyroscan (0.5 T) was used, and spin echo measurements (echo time 30 ms) were made before and 20 minutes after intravenous injection of 0.1 mmol/kg gadolinium-DTPA. In all patients contrast enhancement of the infarcted areas was seen after Gd-DTPA. The signal intensities of the infarcted and normal values were used to calculate the intensity ratios. Mean (SD) intensity ratios after Gd-DTPA were significantly increased (1.15 (0.17) v 1.52 (0.29). Intensity ratios were higher in the 17 patients who underwent magnetic resonance imaging more than 72 hours after the onset of symptoms than in the 10 who underwent magnetic resonance imaging earlier, the difference being significantly greater after administration of Gd-DTPA (1.38 (0.12) v 1.61 (0.34). When patients were classified according to the site and size of the infarcted areas, or to reperfusion (n = 19) versus non-reperfusion (n = 8), the intensity ratios both before and after Gd-DTPA did not show significant differences. Magnetic resonance imaging with Gd-DTPA improved the identification of acutely infarcted areas, but with current techniques did not identify patients in whom thrombolytic treatment was successful.

Forty-five patients with suspected acute myocardial infarction were examined with magnetic resonance (MR) imaging before and serially up to 30 minutes after intravenous injection of gadolinium diethylenetriaminepentaacetic acid (DTPA), 0.1 mmol/kg of body weight. Coronary angiography after thrombolytic therapy was performed in all patients to assess reperfusion. Intensity ratios between both reperfused and nonreperfused infarcted areas and normal myocardium increased significantly up to 15-20 minutes after administration of Gd-DTPA and were still elevated 30 minutes after injection (P less than .0001). In accordance with the findings in experimental studies, four distribution patterns of infarct enhancement were observed. The overlap in enhancement patterns and similar maximal intensity ratios after Gd-DTPA administration for both reperfused and nonreperfused infarcts preclude a reliable differentiation on the basis of these factors alone. Significant enhancement of both reperfused and nonreperfused infarcts allows adequate infarct imaging up to at least 30 minutes after administration of Gd-DTPA.

To assess the value of the paramagnetic contrast agent Gadolinium (Gd)-DTPA in Magnetic Resonance Imaging (MRI) of acute myocardial infarction (AMI), we studied 20 patients with a first AMI by ECG-gated MRI before and after intravenous administration of 0.15 mmol/kg Gd-DTPA. The MRI studies were performed after a mean of 98 hours (range 15-241) after the acute onset of AMI. Spin-echo measurements (TE 30 msec) were made using a Philips Gyroscan (0.5 Tesla). After performing the baseline MRI scans, the MRI procedure was repeated every 10 minutes for up to 40 minutes following injection of Gd-DTPA. In 18 (90%) patients contrast enhancement in the infarcted myocardial areas was observed after Gd-DTPA. In these patients intensity versus region curves, derived from 9 to 11 adjacent myocardial regions of interest, showed increased signal intensities in the infarcted areas after administration of Gd-DTPA. The precontrast signal intensity ratio between infarcted and normal myocardium was 1.14 +/- 0.15 (mean +/- SD); the postcontrast ratios at 10 minutes were 1.41 +/- 0.21 (P less than 0.05), at 20 minutes 1.61 +/- 0.19 (P less than 0.01), at 30 minutes 1.43 +/- 0.20 (P less than 0.05), and at 40 minutes 1.33 +/- 0.20 (P = NS). It is concluded that MRI using the contrast agent Gd-DTPA significantly improves the visualization and detection of infarcted myocardial areas in patients with AMI and that optimal contrast enhancement is obtained 20 minutes after administration of Gd-DTPA.

The potential of gadolinium (Gd)-DTPA to improve the detection of acute myocardial infarction by MR has been shown in experimental canine studies. To determine its value in humans, we studied five patients 2-17 days after myocardial infarction by using ECG-gated MR before and after administration of 0.1 mmol/kg Gd-DTPA. One patient had a rupture of the interventricular septum, complicating an acute inferior-wall infarction. Spin-echo images were obtained before and immediately after injection of Gd-DTPA and were repeated every 10 min for up to 40 min. In four patients, intensity-vs-time curves revealed increasing signal intensity in the infarcted area in the first 20 min after injection of gadolinium. Contrast between normal and infarcted myocardium was greatest 20-30 min after Gd-DTPA injection. In one patient, increasing signal intensity of the infarcted myocardium was observed up to 40 min after Gd-DTPA injection. The precontrast intensity ratio between infarcted and normal myocardium was 1.1 at echo time (TE) = 30 msec and was 1.4 at TE = 60 msec (p less than .05). The postcontrast intensity ratio was 1.6, which was not statistically different from the ratio at TE = 60 msec but which was significantly higher than the ratio at TE = 30 msec (p less than .01). Infarct definition was substantially improved on postcontrast images. The septal rupture was clearly seen, and the infarcted myocardium surrounding the septal rupture showed enhancement on postcontrast images. These results suggest that Gd-DTPA can improve MR visualization and detection of acute myocardial infarction.